Place conditioning with cocaine and the dopamine uptake inhibitor GBR12783

NeuroReport

Volumn 7, Issue 18, 1996, Pages 2839-2842

  Le Pen, Gwenaëlle ^a   Duterte Boucher, Dominique ^a   Costentin, Jean ^a  

^a UNIVERSITÉ DE ROUEN   (France)

Author keywords

Cocaine; Conditioned place preference; Dopamine uptake inhibitors; GBR12783; Locomotor activity; Rat

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; COCAINE; 1 (2 (DIPHENYLMETHOXY)ETHYL) 4 (3 PHENYL 2 PROPENYL)PIPERAZINE; 1-(2-(DIPHENYLMETHOXY)ETHYL)-4-(3-PHENYL-2-PROPENYL)PIPERAZINE; DOPAMINE UPTAKE INHIBITOR; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONDITIONING; CONTROLLED STUDY; DOPAMINE UPTAKE; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REWARD; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; INSTRUMENTAL CONDITIONING; MOTOR ACTIVITY; SPRAGUE DAWLEY RAT;

ANIMALS; COCAINE; CONDITIONING, OPERANT; DOPAMINE UPTAKE INHIBITORS; INJECTIONS, INTRAPERITONEAL; MALE; MOTOR ACTIVITY; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; REWARD;

EID: 0030299868     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199611250-00005     Document Type: Article

References (25)

1. Koe BK. J Pharmacol Exp Ther 199, 649-661 (1976).
2. Reith MEA, Meisler BE, Sershen H et al. Biochem Pharmacol 35, 1123-1129 (1986).
3. Ritz MC, Lamb RJ, Goldberg SR et al. Science 237, 1219-1223 (1987).
4. Kalivas PW and Stewart J. Brain Res Rev 16, 223-244 (1991).
5. Woolverton WL and Johnson KM. Trends Pharmacol Sci 13, 193-200 (1992).
6. Van Der Zee P, Hoger HS, Gootjes J et al. Eur J Med Chem 15, 363-370 (1980).
7. Bergman J, Madras BK, Johnson SE et al. J Pharmacol Exp Ther 251, 150-155 (1989).
8. Melia KF and Spealman RD. J Pharmacol Exp Ther 258, 626-632 (1991).
9. Witkin JM, Nichols DE, Terry P et al. J Pharmacol Exp Ther 257, 706-713 (1991).
10. Roberts DC. Psychopharmacology 111, 202-206 (1993).
11. Maldonado-Irizarry CS, Stellar JR and Kelley AE. Pharmacol Biochem Behav 48, 915-920 (1994).
12. Bonnet J-J and Costentin J. Eur J Pharmacol 121, 199-209 (1986).
13. Vaugeois J-M, Bonnet J-J and Costentin J. Eur J Pharmacol 210, 77-84 (1992).
14. Boulay D, Duterte-Boucher D, Leroux-Nicollet I et al. J Pharmacol Exp Ther 278, 330-337 (1996).
15. Bozarth MA. Conditioned place preference: A parametric analysis using systemic heroin injections. In: Bozarth MA, ed. Methods of Assessing the Reinforcing Properties of Abused Drugs. New York: Springer-Verlag, 1987: 241-273.
16. Hoffman DC. Brain Res Bull 23, 373-387 (1989).
17. Wojnicki FHE and Glowa JR. Psychopharmacology 123, 34-41 (1996).
18. Spyraki C, Fibiger HC and Phillips AG. Brain Res 253, 196-203 (1982).
19. Spealman RD. J Pharmacol Exp Ther 275, 53-62 (1995).
20. Cunningham KA and Callahan PM. Psychopharmacology 104, 177-180 (1991).
21. Howell LL and Byrd LD. J Pharmacol Exp Ther 276, 1551-1559 (1995).
22. Hemby SE, Jones GH, Justice JB Jr et al. Psychopharmacology 106, 330-336 (1992).
23. Robledo P, Maldonado R and Koob GF. Brain Res 622, 105-112 (1993).
24. Gong W, Neill DB and Justice JB Jr. Pharmacol Biochem Behav 53, 191-196 (1996).
25. Miner LL, Drago J, Chamberlain PM et al. NeuroReport 6, 2314-2316 (1995).